- April 26, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Dengvaxia
Synonyms :
dengue vaccine
Class :
Vaccines
See Pediatric Dosing
Dosage Forms & Strengths
Powder for injection
4.5-6 log10 CCID-50 per vial
CCID-50 = 50% cell culture infectious dose
Age: 9-16 years
0.5 mL subcutaneously (SC) of 3 doses at months of 0, 6, and 12
See Pediatric Dosing
immunosuppressants may enhance the adverse/toxic effect of dengue Vaccine
immunosuppressants may enhance the adverse/toxic effect of dengue Vaccine
immunosuppressants may enhance the adverse/toxic effect of dengue Vaccine
immunosuppressants may enhance the adverse/toxic effect of dengue Vaccine
immunosuppressants may enhance the adverse/toxic effect of dengue Vaccine
immunosuppressants increase the toxicity of the dengue tetravalent vaccine
immunosuppressants increase the toxicity of the dengue tetravalent vaccine
immunosuppressants increase the toxicity of the dengue tetravalent vaccine
immunosuppressants increase the toxicity of the dengue tetravalent vaccine
immunosuppressants increase the toxicity of the dengue tetravalent vaccine
may have an increased adverse effect when combined with dengue tetravalent vaccine
may have an increased adverse effect when combined with dengue tetravalent vaccine
may have an increased adverse effect when combined with dengue tetravalent vaccine
atoltivimab/maftivimab/odesivimab
The immunosuppressive properties of odesivimab/maftivimab/atoltivimab reduce the effects of the dengue vaccination
may have an increasingly adverse effect when combined with dengue vaccine
may have an increasingly adverse effect when combined with dengue vaccine
may have an increasingly adverse effect when combined with dengue vaccine
may have an increasingly adverse effect when combined with dengue vaccine
may have an increasingly adverse effect when combined with dengue vaccine
when both drugs are combined, there may be an increased risk or severity of infection from the vaccine
interaction with methotrexate may diminish the therapeutic effects of the vaccine, avoid combination
interaction with trimetrexate may diminish the therapeutic effects of the vaccine, avoid combination
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine
interaction with trimetrexate may diminish the therapeutic effects of the vaccine, avoid combination
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine
when both drugs are combined, there may be a decreased therapeutic effect of the vaccine
when both drugs are combined, there may be a decreased therapeutic effect of the vaccine
it may reduce the therapeutic efficacy of the dengue vaccine
may decrease the effects of each other
may increase the adverse effects of corticosteroids
may increase the toxic effect of immunosuppressants
may increase the toxic effect of immunosuppressants
may increase the toxic effect of immunosuppressants
may increase the adverse effect of Immunosuppressants
may increase the adverse effect of Immunosuppressants
may increase the adverse effect of Immunosuppressants
may increase the toxic effect of Immunosuppressants
may increase the adverse/toxic effect of dengue vaccine
may increase the adverse/toxic effect of dengue vaccine
may increase the adverse/toxic effect of dengue vaccine
may increase the adverse/toxic effect of dengue vaccine
may increase the adverse/toxic effect of dengue vaccine
It may diminish the immunosuppressive effects when combined with risankizumab
By immunosuppressive effects, the effect of vaccine activity decreases and results in risk of infection.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
when dengue vaccine is combined with melphalan the therapeutic efficacy of the vaccine decreases
when both the drugs combine the effect of vaccine decreases by immunosuppressive effects and increase the risk of infection.
when thiotepa and dengue vaccine combines, thiotepa decreases the effects of the vaccine by immunosuppressive effects
live vaccines are not recommended, oncological agents may diminish the therapeutic effects of live vaccines
brentuximab vedotin has a reduced impact on the efficacy of the dengue vaccine, caused due to immunosuppression. Risk of infection persists.
may diminish the therapeutic effects of the vaccine
may reduce the immune response to dengue vaccine due to immunosuppressive effects
may diminish immune response to dengue vaccine
the effect of the dengue vaccine is decreased by gemcitabine through immunosuppression/risk of infection
may diminish immune response to dengue vaccine
may diminish immune response to dengue vaccine
the effect of the dengue vaccine is decreased by fluorouracil through immunosuppression/risk of infection
may reduce therapeutic effects of dengue vaccine
when both drugs are combined, there may be an increased risk or severity of infection
encorafenib, in combination with the dengue vaccine, shows immunosuppression. It decreases the effect of the dengue vaccine
when both drugs are combined, there may be an increased risk of infection
when both drugs are combined, there may be an increased risk of infection
in combination with the dengue vaccine, neratinib decreases its effect by immunosuppression
may diminish the therapeutic effects of the vaccine
Adverse drug reactions within 7 days
Frequency defined
Any grade
Myalgia (20-29.2%)
Asthenia
Swelling (1.6-3.5%)
Erythema (1.5-4.1%)
Malaise (19.3-24.5%)
Headache (29.6-39.9%)
Pain (22.5-32.4%)
Fever
Grade 3
Asthenia
Pain
Fever
Erythema
Malaise
Headache
Myalgia
Pregnancy warnings:
US FDA pregnancy category: N/A
Lactation:
Excreted into human milk is Unknown
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: dengue vaccine
Why do we use dengue vaccine?
dengue vaccine is used to protect individuals against dengue fever, a viral disease caused by the dengue virus. Here are some reasons why dengue vaccines are used:
The primary goal of dengue vaccination is to prevent dengue fever, which can range from a mild flu-like illness to severe and potentially life-threatening forms such as dengue hemorrhagic fever and dengue shock syndrome. Vaccination can reduce the risk of developing these severe forms of dengue.
Dengue is a significant public health concern in many parts of the world, particularly in tropical and subtropical regions. By vaccinating individuals at risk, the spread of the dengue virus can be reduced, leading to a decrease in the overall disease burden and the number of cases.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
